Novago Therapeutics AG

[Available On-Demand]
Search General Info
Search Education
Search Partnering Companies
NovaGo Therapeutics AG, a spin-off biotech company from the University of Zurich, Switzerland, dedicated to the development of human antibody therapeutics that promote regeneration after cerebral stroke and retinopathy.
Stroke is a leading cause of adult disability and represents a major health problem worldwide. The current standard of care has significant shortcomings, leaving more than 50% of all stroke patients severely and permanently disabled. Stroke often creates life-long functional impairment and burden to the victims, the wider society and healthcare providers.
NovaGo is developing human antibody therapeutics against Nogo-A, the most potent inhibitor of nerve fiber regeneration after injury of the central nervous system.
Company Type:
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Switzerland
Year Founded:
2015
Main Therapeutic Focus:
Lead Product in Development:
NG004
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
1
Speaker
photo
CEO
Novago Therapeutics